Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.
The increased use of opioid pain medication has been mirrored by the increased misuse and abuse of these drugs. As part of a multidisciplinary approach to this epidemic, pharmaceutical companies, with the encouragement of the Food and Drug Administration, have increased the development of abuse-deterrent formulations. While all have the goal of treating pain while mitigating misuse and abuse, there are different technologies utilized to impart the abuse-deterrent properties. The goal of this paper is to review the basis of abuse-deterrent formulations, the different types and approaches of some of the abuse-deterrent products, and their current regulatory status in the USA.
Rocky Mountain Poison and Drug Center-Denver Health, Denver, CO, USA. Tammi.Schaeffer@rmpdc.org
Tammi
T
Schaeffer
D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000737:chemistry* / Q000627:therapeutic use*; D002047:Buprenorphine / Q000494:pharmacology; D002626:Chemistry, Pharmaceutical / Q000331:legislation & jurisprudence; D003913:Dextroamphetamine / Q000494:pharmacology; D006801:Humans; D000069478:Lisdexamfetamine Dimesylate; D009020:Morphine / Q000494:pharmacology; D009271:Naltrexone / Q000494:pharmacology; D009293:Opioid-Related Disorders / Q000453:epidemiology* / Q000517:prevention & control*; D010146:Pain / Q000188:drug therapy; D063487:Prescription Drug Misuse; D014481:United States; D014486:United States Food and Drug Administration
D000701:Analgesics, Opioid; D002047:Buprenorphine; D009271:Naltrexone; D009020:Morphine; D000069478:Lisdexamfetamine Dimesylate; D003913:Dextroamphetamine